Dietary Control of Arachidonic Acid Metabolism
First Claim
1. A method of treating an inflammatory disorder, or a disorder having an inflammatory component, in a mammalian subject in need of such treatment by administering to said subject an effective amount of a composition in unit dosage form for delivery of a daily dose of said composition, said composition consisting essentially of:
- (i) an effective amount of γ
-linolenic acid (GLA) for increasing dihomogammalinolenic acid (DGLA) levels in the inflammatory cells of said mammalian subject, thereby inhibiting the metabolism of arachidonic acid;
(ii) an effective amount of a Δ
5 desaturase inhibitor for inhibiting accumulation of arachidonic acid in the serum of said mammalian subject; and
, optionally, (iii) an effective amount of a competitive inhibitor of arachidonic acid metabolism.
1 Assignment
0 Petitions
Accused Products
Abstract
Compositions for the treatment of symptoms of inflammatory disorders may include gamma-linolenic acid or dihomogammalinolenic acid, an inhibitor of Δ5 desaturase, and optionally stearidonic acid or ω-3 arachidonic acid. Preferred formulations may be in the form of a good tasting, preferably milk or fruit based drink, or a dried powder. Compositions reduce inflammation and inhibit increase in serum arachidonic acid associated with gamma-linolenic acid.
-
Citations
28 Claims
-
1. A method of treating an inflammatory disorder, or a disorder having an inflammatory component, in a mammalian subject in need of such treatment by administering to said subject an effective amount of a composition in unit dosage form for delivery of a daily dose of said composition, said composition consisting essentially of:
-
(i) an effective amount of γ
-linolenic acid (GLA) for increasing dihomogammalinolenic acid (DGLA) levels in the inflammatory cells of said mammalian subject, thereby inhibiting the metabolism of arachidonic acid;
(ii) an effective amount of a Δ
5 desaturase inhibitor for inhibiting accumulation of arachidonic acid in the serum of said mammalian subject; and
, optionally,(iii) an effective amount of a competitive inhibitor of arachidonic acid metabolism. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)
-
Specification